PROCEPT BioRobotics CorpPRCTEarnings & Financial Report
PROCEPT BioRobotics Corp is a medical tech firm developing and commercializing robotic surgical solutions for urological care. Its flagship AquaBeam system provides image-guided minimally invasive therapy for benign prostatic hyperplasia, serving providers and patients across North America, Europe and global markets.
PRCT Q1 FY2026 Key Financial Metrics
Revenue
$83.1M
Gross Profit
$53.9M
Operating Profit
$-3.4M
Net Profit
$-31.6M
Gross Margin
64.9%
Operating Margin
-4.1%
Net Margin
-38.1%
YoY Growth
20.2%
EPS
$-0.56
PROCEPT BioRobotics Corp Q1 FY2026 Financial Summary
PROCEPT BioRobotics Corp reported revenue of $83.1M (up 20.2% YoY) for Q1 FY2026, with a net profit of $-31.6M (down 27.9% YoY) (-38.1% margin). Cost of goods sold was $29.2M, operating expenses totaled $57.4M.
Key Financial Metrics
| Total Revenue | $83.1M |
|---|---|
| Net Profit | $-31.6M |
| Gross Margin | 64.9% |
| Operating Margin | -4.1% |
| Report Period | Q1 FY2026 |
Revenue Breakdown
PROCEPT BioRobotics Corp Q1 FY2026 revenue of $83.1M breaks down across 4 segments, led by Handpieces and other consumables at $43.0M (51.7% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Handpieces and other consumables | $43.0M | 51.7% |
| System sales and rentals | $23.4M | 28.1% |
| Other | $11.1M | 13.4% |
| Service | $5.6M | 6.8% |
PROCEPT BioRobotics Corp Revenue by Segment — Quarterly Trend
PROCEPT BioRobotics Corp revenue by segment across the last 4 reported quarters, showing how each business line (such as Handpieces and other consumables and System sales and rentals) has evolved quarter over quarter.
| Segment | Q1 FY2026 | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 |
|---|---|---|---|---|
| Handpieces and other consumables | $43.0M | — | — | — |
| System sales and rentals | $23.4M | — | — | — |
| Other | $11.1M | $9.8M | — | — |
| Service | $5.6M | — | — | — |
PROCEPT BioRobotics Corp Annual Revenue by Year
PROCEPT BioRobotics Corp annual revenue history includes year-by-year totals (for example, 2025 revenue was $308.1M).
PROCEPT BioRobotics Corp Quarterly Revenue & Net Profit History
PROCEPT BioRobotics Corp results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2026 | $83.1M | +20.2% | $-31.6M | -38.1% |
| Q4 FY2025 | $76.4M | +11.9% | $-29.8M | -39.1% |
| Q3 FY2025 | $83.3M | +42.8% | $-21.4M | -25.7% |
| Q2 FY2025 | $79.2M | +48.4% | $-19.6M | -24.7% |
| Q1 FY2025 | $69.2M | +55.3% | $-24.7M | -35.8% |
| Q4 FY2024 | $68.2M | +56.6% | $-18.9M | -27.6% |
| Q3 FY2024 | $58.4M | +66.3% | $-21.0M | -35.9% |
| Q2 FY2024 | $53.4M | +61.2% | $-25.6M | -48.0% |
Income Statement
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $53.4M | $58.4M | $68.2M | $69.2M | $79.2M | $83.3M | $76.4M | $83.1M |
| YoY Growth | 61.2% | 66.3% | 56.6% | 55.3% | 48.4% | 42.8% | 11.9% | 20.2% |
Balance Sheet
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $374.4M | $374.1M | $534.0M | $519.4M | $513.1M | $511.5M | $508.1M | $487.1M |
| Liabilities | $122.6M | $132.9M | $131.8M | $130.2M | $127.3M | $131.3M | $142.2M | $139.4M |
| Equity | $251.8M | $241.2M | $402.2M | $389.2M | $385.8M | $380.3M | $365.9M | $347.7M |
Cash Flow
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|
| Operating CF | $-15.7M | $-18.8M | $-32.4M | $-17.0M | $-15.0M | $-6.6M | $-10.3M |